Welcome to our dedicated page for Psyence Biomedical Ltd. news (Ticker: PBM), a resource for investors and traders seeking the latest updates and insights on Psyence Biomedical Ltd. stock.
Psyence Biomedical Ltd. (Nasdaq: PBM), also known as Psyence BioMed, is a biopharmaceutical and life sciences biotechnology company focused on nature-derived psilocybin and ibogaine-based psychedelic medicine. Its news flow reflects activity across clinical development, manufacturing, capital markets, and strategic partnerships.
Readers of the PBM news page can expect updates on the company’s Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in palliative care or in patients with cancer. News releases describe milestones such as patient dosing, expansion of clinical sites in Australia, and ethics approvals for the use of PsyLabs’ psilocybin product in the trial.
The company also issues announcements on its ibogaine operations and supply chain, including the establishment of sustainable iboga bark sourcing in Africa and the production of GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) and Total Alkaloid Extracts through its partner PsyLabs. These updates highlight progress in securing psychedelic active pharmaceutical ingredients for clinical and therapeutic markets.
Other PBM news items cover strategic investments and financial decisions, such as follow-on investments in PsyLabs, share consolidation (reverse stock split) actions, and capital management frameworks that include potential share repurchase programs, as described by the company. Communications may also address leadership changes, board appointments, and corporate governance developments disclosed in conjunction with SEC filings.
In addition, Psyence BioMed publishes news on its psilocybin longevity research initiative, which examines biological markers associated with aging, and on its broader positioning in the emerging psychedelics and longevity sectors. Investors and observers who follow PBM news can use this page to track the company’s clinical progress, manufacturing capabilities, and regulatory and capital markets updates over time.
Psyence BioMed (Nasdaq: PBM) exported GMP-manufactured natural psilocybin NPX-5 (1 mg and 5 mg capsules) to Australia to supply its ongoing Phase IIb trial for Adjustment Disorder in palliative oncology.
The multi-center, double-blind trial is enrolling 87 participants across Australian sites including Melbourne and Perth; patient dosing began in late 2025 and newly enrolled patients will receive NPX-5. PsyLabs manufactured the product and holds a 49.98% equity stake in Psyence BioMed.
Psyence BioMed (Nasdaq: PBM) announced that Psyence Labs exercised a previously disclosed put option, triggering a share-for-share equity investment in PsyLabs valued at US$5,000,000.
The Company will receive 2,900 PsyLabs shares and issue 1,146,159 PBM shares; closing is expected on or about February 25, 2026. No cash will change hands and the transaction would leave PsyLabs with ~49.98% of PBM outstanding shares.
Psyence BioMed (Nasdaq: PBM) reported results from its Annual and Special Meeting held Feb 12, 2026. Shareholders approved all matters, including election of directors, appointment of MNP LLP as auditors, and a special resolution authorizing the Board to implement one or more share consolidations up to 250:1.
All director nominees listed in the company's management information circular dated Jan 2, 2026 were elected to hold office until the next annual meeting. The Board will disclose final consolidation ratio and effective date if it decides to proceed, subject to regulatory and exchange approvals.
Psyence BioMed (Nasdaq: PBM) approved a Put Option Agreement with PsyLabs on Feb 13, 2026 to secure long-term access to GMP pharmaceutical-grade psilocybin and ibogaine supply while preserving near-term cash. The option allows PsyLabs to require a future share-for-share equity investment at fair market value, and the Board formed a Special Committee and relied on an independent valuation.
Psyence BioMed (Nasdaq: PBM) announced a settlement resolving a direct shareholder claim by KAOS Capital dated Jan 14 and Jan 26, 2026. The Ontario Superior Court dismissed KAOS's application and awarded costs of CDN $75,000. Under the settlement the company will pay US $1,500,000 and KAOS will sell all its shares at US $5 per share, include a full retraction and mutual release, and KAOS is released from the Costs Award. The company expects to fund the payment from cash on hand and record it under applicable accounting standards.
Psyence BioMed (Nasdaq: PBM) announced its 1-for-6.25 reverse stock split will become effective at market open on February 2, 2026. The consolidation changes issued and outstanding common shares from 6,388,604 to 1,022,177 and keeps the ticker PBM.
Outstanding warrants and equity instruments will be adjusted proportionately; new CUSIP is 74449F407. No fractional shares will be issued; fractions are rounded per disclosed rules. Book-entry holders need take no action; beneficial holders should consult brokers.
Psyence BioMed (Nasdaq: PBM) adjourned its annual and special shareholder meeting scheduled for January 22, 2026 to February 12, 2026 at 9:00 a.m. New York Time / 4:00 p.m. Cape Town Time. The reconvened Meeting will be held at Venture Workspace Riverlands, Office Building 4, Riverlands, 51 Gogosoa Street, Observatory, Cape Town, 7935, South Africa.
The adjournment occurred because the requisite shareholder quorum was not achieved. The company is working with its proxy agents to help obtain quorum for the February 12, 2026 meeting. The record date remains close of business on December 23, 2025. For details of the Meeting business, see the company notice of meeting and management information circular dated January 2, 2026, filed on EDGAR.
Psyence BioMed (Nasdaq: PBM) announced on January 20, 2026 that it has postponed the previously announced 1-for-6.25 reverse stock split, which had been intended to become effective at market open on January 20, 2026. The Board retains discretion to determine if and when the reverse split will be effected.
The company said it will issue a subsequent press release and file any required Nasdaq notifications before setting a new effective date. Until a new date is set, PBM will continue to trade unadjusted on the Nasdaq Capital Market under ticker PBM and CUSIP 74449F308.
Psyence BioMed (Nasdaq: PBM) announced the effective date for a 1-for-6.25 reverse stock split. The consolidation was approved by the board on December 4, 2025, and common shares are expected to trade on a post-consolidated basis starting at market open on January 20, 2026. At the effective time every 6.25 issued shares will be combined into one share; warrants and other equity instruments will be adjusted proportionately. The company had 6,388,604 shares outstanding as of January 14, 2026, which will become 1,022,177 post-consolidation. Trading will remain under the symbol PBM with new CUSIP 74449F407. Fractional shares will be rounded per the announced rules and brokerage-held shares may reflect the change with delay.
Psyence BioMed (Nasdaq: PBM) announced that its Board approved a 2026 Financial Strategy and Capital Management Framework that authorizes a potential share repurchase program. The program allows the company to repurchase common shares from time to time, subject to liquidity, valuation, regulatory, Nasdaq, and corporate law conditions, and would be executed through an independent third-party broker. Repurchases may occur over the next six to twelve months if prices reflect a significant discount to the Board's assessment of underlying value, provided operational liquidity and planned clinical and regulatory milestones remain funded. The company is not obligated to repurchase shares and may modify or terminate the program.